Portrazza FDA Approval History
Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer.
Development Timeline for Portrazza
|Nov 24, 2015||Approval FDA Approves Portrazza (necitumumab) for Advanced Squamous Non-Small Cell Lung Cancer|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.